Butyrophilins: Dynamic Regulators of Protective T Cell Immunity in Cancer

Rinkee Kumari; Elaheh Sadat Hosseini; Kristen E. Warrington; Tyler Milonas; Kyle K. Payne

doi:https://doi.org/10.3390/ijms24108722

Butyrophilins: Dynamic Regulators of Protective T Cell Immunity in Cancer

Rinkee Kumari, Elaheh Sadat Hosseini, Kristen E. Warrington, Tyler Milonas, Kyle K. Payne

Research output: Contribution to journal › Review article › peer-review

Abstract

The efficacy of current immunotherapies remains limited in many solid epithelial malignancies. Recent investigations into the biology of butyrophilin (BTN) and butyrophilin-like (BTNL) molecules, however, suggest these molecules are potent immunosuppressors of antigen-specific protective T cell activity in tumor beds. BTN and BTNL molecules also associate with each other dynamically on cellular surfaces in specific contexts, which modulates their biology. At least in the case of BTN3A1, this dynamism drives the immunosuppression of αβ T cells or the activation of Vγ9Vδ2 T cells. Clearly, there is much to learn regarding the biology of BTN and BTNL molecules in the context of cancer, where they may represent intriguing immunotherapeutic targets that could potentially synergize with the current class of immune modulators in cancer. Here, we discuss our current understanding of BTN and BTNL biology, with a particular focus on BTN3A1, and potential therapeutic implications for cancer.

Original language	English (US)
Article number	8722
Journal	International journal of molecular sciences
Volume	24
Issue number	10
DOIs	https://doi.org/10.3390/ijms24108722
State	Published - May 2023
Externally published	Yes

ASJC Scopus subject areas

Catalysis
Molecular Biology
Spectroscopy
Computer Science Applications
Physical and Theoretical Chemistry
Organic Chemistry
Inorganic Chemistry

Keywords

butyrophilins
immune oncology
immune suppression
immunotherapy
γδ T cells

Access to Document

https://doi.org/10.3390/ijms24108722

Cite this

@article{1cd0069f764a46b08a8ea66d1b5c566c,

title = "Butyrophilins: Dynamic Regulators of Protective T Cell Immunity in Cancer",

abstract = "The efficacy of current immunotherapies remains limited in many solid epithelial malignancies. Recent investigations into the biology of butyrophilin (BTN) and butyrophilin-like (BTNL) molecules, however, suggest these molecules are potent immunosuppressors of antigen-specific protective T cell activity in tumor beds. BTN and BTNL molecules also associate with each other dynamically on cellular surfaces in specific contexts, which modulates their biology. At least in the case of BTN3A1, this dynamism drives the immunosuppression of αβ T cells or the activation of Vγ9Vδ2 T cells. Clearly, there is much to learn regarding the biology of BTN and BTNL molecules in the context of cancer, where they may represent intriguing immunotherapeutic targets that could potentially synergize with the current class of immune modulators in cancer. Here, we discuss our current understanding of BTN and BTNL biology, with a particular focus on BTN3A1, and potential therapeutic implications for cancer.",

keywords = "butyrophilins, immune oncology, immune suppression, immunotherapy, γδ T cells",

author = "Rinkee Kumari and Hosseini, {Elaheh Sadat} and Warrington, {Kristen E.} and Tyler Milonas and Payne, {Kyle K.}",

note = "Funding Information: This research was funded by V Foundation for Cancer Research (V2022-030), New Jersey Health Foundation (PC138-22), New Jersey Commission on Cancer Research (COCR23PDF002), Ovarian Cancer Research Alliance (ECIG-2023-3-1007), and National Institutes of Health (P30CA072720). Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = may,

doi = "https://doi.org/10.3390/ijms24108722",

language = "English (US)",

volume = "24",

journal = "International journal of molecular sciences",

issn = "1661-6596",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "10",

}

TY - JOUR

T1 - Butyrophilins

T2 - Dynamic Regulators of Protective T Cell Immunity in Cancer

AU - Kumari, Rinkee

AU - Hosseini, Elaheh Sadat

AU - Warrington, Kristen E.

AU - Milonas, Tyler

AU - Payne, Kyle K.

N1 - Funding Information: This research was funded by V Foundation for Cancer Research (V2022-030), New Jersey Health Foundation (PC138-22), New Jersey Commission on Cancer Research (COCR23PDF002), Ovarian Cancer Research Alliance (ECIG-2023-3-1007), and National Institutes of Health (P30CA072720). Publisher Copyright: © 2023 by the authors.

PY - 2023/5

Y1 - 2023/5

N2 - The efficacy of current immunotherapies remains limited in many solid epithelial malignancies. Recent investigations into the biology of butyrophilin (BTN) and butyrophilin-like (BTNL) molecules, however, suggest these molecules are potent immunosuppressors of antigen-specific protective T cell activity in tumor beds. BTN and BTNL molecules also associate with each other dynamically on cellular surfaces in specific contexts, which modulates their biology. At least in the case of BTN3A1, this dynamism drives the immunosuppression of αβ T cells or the activation of Vγ9Vδ2 T cells. Clearly, there is much to learn regarding the biology of BTN and BTNL molecules in the context of cancer, where they may represent intriguing immunotherapeutic targets that could potentially synergize with the current class of immune modulators in cancer. Here, we discuss our current understanding of BTN and BTNL biology, with a particular focus on BTN3A1, and potential therapeutic implications for cancer.

AB - The efficacy of current immunotherapies remains limited in many solid epithelial malignancies. Recent investigations into the biology of butyrophilin (BTN) and butyrophilin-like (BTNL) molecules, however, suggest these molecules are potent immunosuppressors of antigen-specific protective T cell activity in tumor beds. BTN and BTNL molecules also associate with each other dynamically on cellular surfaces in specific contexts, which modulates their biology. At least in the case of BTN3A1, this dynamism drives the immunosuppression of αβ T cells or the activation of Vγ9Vδ2 T cells. Clearly, there is much to learn regarding the biology of BTN and BTNL molecules in the context of cancer, where they may represent intriguing immunotherapeutic targets that could potentially synergize with the current class of immune modulators in cancer. Here, we discuss our current understanding of BTN and BTNL biology, with a particular focus on BTN3A1, and potential therapeutic implications for cancer.

KW - butyrophilins

KW - immune oncology

KW - immune suppression

KW - immunotherapy

KW - γδ T cells

UR - http://www.scopus.com/inward/record.url?scp=85160379016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85160379016&partnerID=8YFLogxK

U2 - https://doi.org/10.3390/ijms24108722

DO - https://doi.org/10.3390/ijms24108722

M3 - Review article

C2 - 37240071

SN - 1661-6596

VL - 24

JO - International journal of molecular sciences

JF - International journal of molecular sciences

IS - 10

M1 - 8722

ER -

Butyrophilins: Dynamic Regulators of Protective T Cell Immunity in Cancer

Abstract

ASJC Scopus subject areas

Keywords

Access to Document

Other files and links

Fingerprint

Cite this